Lord Abbett & CO. LLC Acquires 960,648 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Lord Abbett & CO. LLC boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 66.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,404,895 shares of the company's stock after purchasing an additional 960,648 shares during the quarter. Lord Abbett & CO. LLC owned about 0.21% of Teva Pharmaceutical Industries worth $53,004,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Oarsman Capital Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $29,000. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $66,000. IFP Advisors Inc lifted its holdings in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after acquiring an additional 1,960 shares during the period. Finally, Quadrant Capital Group LLC boosted its position in Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after purchasing an additional 949 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TEVA has been the topic of a number of research analyst reports. Bank of America cut their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday. UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.15 during trading on Thursday, hitting $15.66. 5,137,242 shares of the stock traded hands, compared to its average volume of 9,935,343. The stock has a market cap of $17.75 billion, a price-to-earnings ratio of -10.79, a PEG ratio of 1.44 and a beta of 0.72. The firm's fifty day moving average is $15.13 and its 200-day moving average is $17.52. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.